Research Progress of the Effects of Long-Term Use of Proton Pump Inhibitors on Non-Alcoholic Fatty Liver Disease

No abstract is available for this paper.

• Publication year

  2024

• Venue

  Advances in Clinical Medicine

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.12677/acm.2024.1441127
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Compared to histamine-2 receptor antagonist, proton pump inhibitor induces stronger oral-to-gut microbial transmission and gut microbiome alterations: a randomised controlled trial

  2023cited by this paper
• Association between gut microbiota and NAFLD/NASH: a bidirectional two-sample Mendelian randomization study

  2023cited by this paper
• Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis

  2023cited by this paper
• Proton Pump Inhibitor Pantoprazole Modulates Intestinal Microbiota and Induces TLR4 Signaling and Fibrosis in Mouse Liver

  2022cited by this paper
• Proton pump inhibitor use - a risk factor for inflammatory bowel disease or an innocent bystander?

  2021cited by this paper
• Oral Supplementation of Sodium Butyrate Attenuates the Progression of Non-Alcoholic Steatohepatitis

  2020cited by this paper
• Butyrate in IBD therapy.

  2020cited by this paper
• Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications

  2020cited by this paper
• Proton pump inhibitors use and the risk of fatty liver disease: A nationwide cohort study

  2020cited by this paper
• Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders

  2020cited by this paper
• Microbiome Signatures Associated with Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.

  2019cited by this paper
• Connection between gut microbiome and the development of obesity

  2019cited by this paper
• Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified

  2019cited by this paper
• Mechanisms of NAFLD development and therapeutic strategies

  2018cited by this paper
• Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice

  2018cited by this paper
• The role of the microbiome in NAFLD and NASH

  2018cited by this paper
• Oral microbiome alterations of healthy volunteers with proton pump inhibitor

  2018cited by this paper
• Gut microbiome may contribute to insulin resistance and systemic inflammation in obese rodents: a meta-analysis.

  2018cited by this paper
• The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.

  2017cited by this paper
• Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus

  2017cited by this paper
• Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis

  2017cited by this paper
• The influence of proton pump inhibitors and other commonly used medication on the gut microbiota

  2017cited by this paper
• Proton pump inhibitors as risk factor for metabolic syndrome and hepatic steatosis in coeliac disease patients on gluten-free diet

  2017cited by this paper
• EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

  2016cited by this paper
• Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

  2016cited by this paper
• The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota

  2016cited by this paper
• Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance.

  2016cited by this paper
• Translational research into gut microbiota: new horizons on obesity treatment: updated 2014.

  2015cited by this paper
• Proton pump inhibitors alter the composition of the gut microbiota

  2015cited by this paper
• Proton pump inhibitors affect the gut microbiome

  2015cited by this paper
• Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial.

  2015cited by this paper
• Hepatic TLR4 signaling in obese NAFLD.

  2015cited by this paper
• Role of the normal gut microbiota.

  2015cited by this paper
• Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis.

  2013cited by this paper
• The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

  2012cited by this paper
• Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis

  2012cited by this paper
• Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed.

  2012cited by this paper
• Contribution of Gut Bacteria to Liver Pathobiology

  2010cited by this paper
• Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease

  2009cited by this paper
• Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis.

  2007cited by this paper
• TLR4 enhances TGF-β signaling and hepatic fibrosis

  2007cited by this paper
• Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression

  2007cited by this paper

• No citing papers are available for this paper.